论文部分内容阅读
目的探讨表皮生长因子受体(EGFR)在晚期肺腺癌患者中的表达及其意义。方法收集60例晚期肺腺癌患者的胸腔积液及活检肺癌组织,采用免疫组化检测EGFR的表达,并探讨其表达与临床病理特征的关系。结果 EGFR在胸腔积液及肺癌组织中的阳性表达率分别为75.0%(45/60)、63.3%(38/60),两者差异无统计学意义(P>0.05)。结论 EGFR均高表达于肺腺癌胸腔积液及腺癌组织,且与年龄、性别、吸烟史、分化程度及肿瘤的大小无明显相关,可指导肺腺癌患者的靶向治疗。
Objective To investigate the expression of epidermal growth factor receptor (EGFR) in patients with advanced lung adenocarcinoma and its significance. Methods Sixty patients with advanced lung adenocarcinoma were collected for pleural effusion and biopsy of lung cancer. The expression of EGFR was detected by immunohistochemistry and the relationship between the expression of EGFR and clinicopathological features was analyzed. Results The positive rates of EGFR in pleural effusion and lung cancer tissues were 75.0% (45/60) and 63.3% (38/60), respectively, with no significant difference (P> 0.05). Conclusions EGFR is highly expressed in pleural effusion and adenocarcinoma of lung adenocarcinoma. There is no significant correlation between EGFR and age, sex, smoking history, differentiation degree and the size of the tumor. It can guide the targeted therapy of patients with lung adenocarcinoma.